Xvivo Perfusion Price To Sales vs. Cash And Equivalents
| XVIVO Stock | SEK 480.00 7.50 1.59% |
For Xvivo Perfusion profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Xvivo Perfusion to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Xvivo Perfusion AB utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Xvivo Perfusion's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Xvivo Perfusion AB over time as well as its relative position and ranking within its peers.
Xvivo |
Xvivo Perfusion AB Cash And Equivalents vs. Price To Sales Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Xvivo Perfusion's current stock value. Our valuation model uses many indicators to compare Xvivo Perfusion value to that of its competitors to determine the firm's financial worth. Xvivo Perfusion AB is rated first in price to sales category among its peers. It is rated first in cash and equivalents category among its peers creating about 24,039,699 of Cash And Equivalents per Price To Sales. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Xvivo Perfusion's earnings, one of the primary drivers of an investment's value.Xvivo Cash And Equivalents vs. Price To Sales
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Xvivo Perfusion |
| = | 16.58 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Xvivo Perfusion |
| = | 398.7 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Xvivo Cash And Equivalents Comparison
Xvivo Perfusion is currently under evaluation in cash and equivalents category among its peers.
Xvivo Perfusion Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Xvivo Perfusion, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Xvivo Perfusion will eventually generate negative long term returns. The profitability progress is the general direction of Xvivo Perfusion's change in net profit over the period of time. It can combine multiple indicators of Xvivo Perfusion, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Xvivo Perfusion AB , a medical technology company, provides solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation. Xvivo Perfusion AB was founded in 1998 and is headquartered in Gothenburg, Sweden. Xvivo Perfusion operates under Medical Devices classification in Sweden and is traded on Stockholm Stock Exchange. It employs 45 people.
Xvivo Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Xvivo Perfusion. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Xvivo Perfusion position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Xvivo Perfusion's important profitability drivers and their relationship over time.
Use Xvivo Perfusion in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Xvivo Perfusion position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xvivo Perfusion will appreciate offsetting losses from the drop in the long position's value.Xvivo Perfusion Pair Trading
Xvivo Perfusion AB Pair Trading Analysis
The ability to find closely correlated positions to Xvivo Perfusion could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Xvivo Perfusion when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Xvivo Perfusion - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Xvivo Perfusion AB to buy it.
The correlation of Xvivo Perfusion is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Xvivo Perfusion moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Xvivo Perfusion AB moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Xvivo Perfusion can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Xvivo Perfusion position
In addition to having Xvivo Perfusion in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Disruptive Technologies Thematic Idea Now
Disruptive Technologies
New or established technology companies and funds across multiple sectors that are involved in development or marketing of products or services that experience disruptive trends and that are at the forefront of discussions on Wall Street. The Disruptive Technologies theme has 64 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Disruptive Technologies Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Xvivo Stock Analysis
When running Xvivo Perfusion's price analysis, check to measure Xvivo Perfusion's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xvivo Perfusion is operating at the current time. Most of Xvivo Perfusion's value examination focuses on studying past and present price action to predict the probability of Xvivo Perfusion's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xvivo Perfusion's price. Additionally, you may evaluate how the addition of Xvivo Perfusion to your portfolios can decrease your overall portfolio volatility.